Can a Custom-Made vaccine train the immune system to fight brain cancer?

NCT ID NCT07762716

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This early-stage trial is testing a personalized cancer vaccine called BreakVax, designed from each patient's own tumor, in combination with standard chemotherapy and immunotherapy drugs. The goal is to see if this multi-pronged approach can safely and effectively boost the immune system's ability to attack glioblastoma, an aggressive brain cancer. The study involves adults with glioblastoma and will first check safety, then look at whether the treatment improves overall survival at 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
A personalized peptide-based cancer immunotherapy (BreakVax) combined with ipilimumab, pembrolizumab, chemotherapy, losartan, and aspirin
What this could lead to
If successful, this approach could offer a new, personalized treatment option for glioblastoma, potentially improving survival by training the immune system to target each patient's unique tumor.
What could go wrong
This is an early-phase trial with only 10 participants, so results may not apply broadly. The combination therapy carries risks of immune-related side effects, and manufacturing the personalized vaccine may fail for some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA (GBM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Miami Herbert Wertheim Cancer Institute

    Miami, Florida, 33176, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.